Aclaris Therapeutics

Pennsylvania, United States · Healthcare · 56 employees

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Funding history

Funding Round — $80.0M — Dec 2024
Funding Round — $11.0M — Apr 2020
Funding Round — $10.0M — Aug 2018
Funding Round — $10.0M — Aug 2017
Funding Round — $20.0M — Jun 2016

Recent signals

Jan 06, 2026: SEC 8-K (7.01): On January 6, 2026, Aclaris Therapeutics, Inc. disclosed interim results from its first-in-human Phase 1a single and multiple ascending dose trial of the anti-TSLP/IL-4Rα bispecific antibody, ATI-052. This filing includes an announcement of a forthcoming webcast and conference call to discuss these interim results. The specifics of the trial results indicate a significant advancement in their drug development process, showcasing the efficacy and safety of ATI-052. Accompanying documents, including a press release and presentation slides, are provided as exhibits.
Apr 29, 2025: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Dec 04, 2024: Raised $80.0M
Apr 08, 2020: Raised $11.0M
Aug 13, 2018: Raised $10.0M
Aug 14, 2017: Raised $10.0M
Jun 14, 2016: Raised $20.0M
Sep 11, 2015: Raised $40.0M

See plans & pricing → Track Aclaris Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.